ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part three of her interview, Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, makes the case that commercial strategy must now inform clinical development from the earliest stages. Indication selection, trial design, and endpoint choices all require commercial input upfront rather than being treated as development decisions subject to post-hoc commercialization planning.
• In a contributed article from Almac Clinical Technologies, authors examined why real-time AI-enabled decision-making only accelerates development when trials have coordinated operational infrastructure for randomization, supply management, and workflows capable of responding to new insights. The real readiness question is not whether sponsors have AI but whether their trial operating models can absorb faster information and respond in a controlled way without disrupting execution or compliance.
• In the pilot episode of Trial and Edit, we examined why sponsor-built AI tools are falling short at the site level, featuring insight from Abraham Gutman of AG Mednet, and an exclusive clip from Liz Beatty of Inato on what cross-asset site partnerships could mean for enrollment. The gap reflects a mismatch between sponsor-side optimization and site-side operational reality.

That's all for today's ACT Brief. Join us next week for more updates shaping clinical operations and drug development. Thanks for listening.